Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypersensitivity Response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    209 result(s) found for: Hypersensitivity Response. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-003703-16 Sponsor Protocol Number: GR-2021-12375001 Start Date*: Information not available in EudraCT
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol - SPHERE.
    Medical condition: Patients with worsening clinical condition requiring MET intervention and in general ward
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10045240 Type I hypersensitivity PT
    23.0 10047065 - Vascular disorders 10083659 Hypotensive crisis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006551-39 Sponsor Protocol Number: SP2007-31 Start Date*: 2008-01-23
    Sponsor Name:Resistentia Pharmaceuticals AB
    Full Title: A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients
    Medical condition: Allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001738 Allergy LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004174-34 Sponsor Protocol Number: Citalopram2017 Start Date*: 2018-04-10
    Sponsor Name:Targid, KU Leuven
    Full Title: A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response
    Medical condition: Functional heartburn and reflux hypersensitivity with incomplete respons to proton pomp inhibitors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004391-11 Sponsor Protocol Number: RCC-DC-2011 Start Date*: 2012-02-08
    Sponsor Name:Masaryk University
    Full Title: Treatment of metastatic renal cell carcinoma using interleukin-12 secreting dendritic cells. Phase I/II clinical trial.
    Medical condition: Metatastic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002916-42 Sponsor Protocol Number: PEOPLE-V712-303 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000008-34 Sponsor Protocol Number: 07.IBS.1 Start Date*: 2007-09-13
    Sponsor Name:North West London Hospitals NHS Trust
    Full Title: Bacteria and host immune response as factors modulating visceral afferent processing in Irritable Bowel Syndrome: manipulation of visceral hypersensitivity with probiotic bacteria
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003323-10 Sponsor Protocol Number: V712-305(EPOPEX) Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005868-10 Sponsor Protocol Number: 6043-PG-PSC-153 Start Date*: 2007-07-24
    Sponsor Name:Laboratorios LETI S.L.
    Full Title: Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Phleum pratense en pacientes con h...
    Medical condition: Rinoconjuntivitis moderada-severa (con o sin asma episódico) inducida por hipersensibilidad frente al polen de gramíneas.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002550-32 Sponsor Protocol Number: VIPES Start Date*: 2012-12-21
    Sponsor Name:DBV Technologies SA
    Full Title: A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.
    Medical condition: Treatment of peanut allergy in adults and children age 6 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012094-35 Sponsor Protocol Number: D5090C00018 Start Date*: 2009-08-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment...
    Medical condition: Patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN) Intended Indication is Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029223 Neuralgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005180-33 Sponsor Protocol Number: CNTO328STM2001 Start Date*: 2009-02-09
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with So...
    Medical condition: Malignant solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000390-30 Sponsor Protocol Number: ML20128 Start Date*: 2006-05-18
    Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
    Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
    Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006149-15 Sponsor Protocol Number: H80-MC-GWBO Start Date*: 2007-06-21
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of treatment interruption on safety and efficacy of exenatide in patients with Type 2 Diabetes.
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002473-19 Sponsor Protocol Number: PNEU-ASTHMA-02 Start Date*: 2018-11-13
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: A MULTICENTER PRAGMATIC TRIAL IN BELGIUM
    Medical condition: Adult patients (at least 18yrs-old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023437-30 Sponsor Protocol Number: A7281006 Start Date*: 2011-09-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA